Drug Trial Radar · NCT03781219
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
45
Planned (sponsor's estimate)
Start
Jul 1, 2018
Primary completion
Dec 1, 2023
Study completion Dec 1, 2023
Sponsor
- Lead sponsor
- Shanghai Kechow Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by HL-085 plus Vemurafenib treatment.
Conditions
- Solid Tumor
Interventions
HL-085Drug
HL-085 ( Capsule) is one MEK inhibitor.
VemurafenibDrug
Vemurafenib ( Tablet) is BRAF inhibitor,
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse EventsTime frame: up to 12 mouths
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China · Recruiting
Beijing Oncology Hospital
Beijing, Beijing Municipality, China · Recruiting
Henan Province Oncology Hospital
Zhengzhou, Henan, China · Recruiting
First Affiliated Hospital, Medicine School of Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.